Introduction
Establishing effective and well tolerated anti-epileptic treatment is particularly important for the elderly population. The aim of care in this vulnerable patient population is the best quality of life with no seizures and the fewest adverse effects from treatment with no drug interactions. Treatment of older patients with antiepileptic drugs (AEDs) is complex and requires special attention to age-related alterations of drug tolerability and metabolism. Patients often have multiple diseases with multiple drug therapy and management requires understanding of the age-related changes in pharmacokinetics and pharmacodynamics of both AEDs and other medication. 1, 2 Epidemiological data show that among all age groups the prevalence of epilepsy is highest above the age of 65. 3 In fact, after stroke and dementia, epileptic seizures and epilepsy represent the third most common health problem in the elderly, cerebrovascular disease being the single most common aetiology underlying epilepsy in the elderly people. 4, 5 Results of the veteran administration study (ILAE Class I evidence) on treatment of geriatric epilepsy suggest that lamotrigine and gabapentin are equally effective as carbamazepine but much better tolerated than immediate release carbamazepine (CBZ-IR). 6 Another study of epilepsy in the elderly (ILAE Class II)
found lamotrigine more effective than CBZ-IR, due to better tolerability of the drug. 7 Finally, another study using the more appropriate slow-release carbamazepine (CBZ-SR) as comparator suggests similar efficacy and tolerability of CBZ-SR and lamotrigine. 8 The major limitation of this study is that it only had an 80%
power to detect a 20% difference in effectiveness between treatment arms only. Therefore, the trial might have been underpowered in order to detect a possible difference between treatment arms.
Despite the fact that the ILAE regards lamotrigine or gabapentin as effective, experts advise the use of lamotrigine or levetiracetam (LEV) as initial monotherapy for elderly adults with focal epilepsy. 9, 10 Levetiracetam has a distinctive clinical profile including anticonvulsive properties against focal and generalized epilepsies with very few toxic effects. 11 The pharmacokinetic profile is very favourable with linear kinetics, low protein binding, no relevant hepatic metabolism, and a low potential for drug interactions. Clinical trials have confirmed the safety and efficacy of LEV in patients with focal epilepsies in a dose range of 1000-3000 mg. [12] [13] [14] Therefore, LEV might be an appropriate candidate for the use in the elderly population. There are, however, only four studies carried out on small numbers of patients, making it difficult to determine the practical value of LEV in elderly patients with epilepsy. [15] [16] [17] [18] Given the paucity of data on its efficacy and safety in this particular section of the population, the aim of this open label, prospective study was to assess the impact of LEV as an add-on therapy on seizure frequency in patients with focal epilepsy aged 65 or above, who failed at least one monotherapy. In addition, this study was designed to document adverse events and treatment success over a longer time period than assessed in regulatory trials carried out mostly only over 12-16 weeks. Regulatory trials are mainly done in younger and more severely affected individuals with a long history of drug-resistant epilepsy. In regulatory trials dosing is fixed and patients have fewer comorbid conditions making it difficult to transfer results into clinical practice. As a result, this study was conducted to provide evidence for clinicians, which would allow them to form an opinion upon the practical, real-life usefulness of LEV outside the stringent boundaries of randomized-controlled protocols.
Methods
For the purposes of this study patients with focal epilepsy were treated prospectively with LEV as add-on antiepileptic medication in an open, observational design over a period of one year. With ethical approval, this work was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki, http://www.wma.net/en/20activities/10ethics/10helsinki/ index.html) for experiments involving humans, all subjects gave the written and informed consent to participate in the study. Patients were eligible for the study if (1) they were 65 years of age or older, (2) had focal epilepsy according to the definition of the International League against Epilepsy and (3) were treated with at least one other antiepileptic drug in monotherapy with insufficient seizure control. 19 The initial starting dose recommended by the protocol was 500 mg LEV BID. This dose could be increased according to efficacy and side effects at the discretion of the investigator by steps of 500 mg BID every 14-28 days up to a maximum daily dose of 1500 mg BID. In patients with renal insufficiency the maximum daily dose was adjusted if the creatinine clearance was below 80 ml/ min to 2000 mg, with further adjustments to 1500 and 1000 mg with a clearance below 50 or 30 ml/min, respectively. After inclusion, follow-up visits were done at 3, 6 and 12 months. At each visit the type and number of seizures, side effects and concomitant drug use was documented. In addition, efficacy and tolerability was rated by physicians and patients on a five-point analogue scale (grades from ''very good'' to ''insufficient'') at last follow-up. All data were collected using paper case report forms. For the purpose of data analysis of this clinical trial two different populations were defined and analysed separately:
safety-population (n = 491): including all patients who received LEV.
per protocol-population (n = 364): patients who were seen at all visits and completed the trial.
Descriptive statistics were calculated for group characteristics like demographic data, type of epilepsy, seizure types, and frequency of side effects. Analyses of differences of these variables were conducted using Chi-square tests or Fisher exact tests. For numerical, normally distributed data two-sided t-tests were used. Changes in seizure frequency were analysed using ANOVA and post hoc two-sided t-tests. A p-value < 0.05 was considered as significant. Due to the open and observational design of the study, inference statistics were carried out exploratively. Accordingly, alpha-adjustments were not conducted. Frequency of other seizure types did not differ with age. The number of patients aged 85 years or older was too small for statistical comparisons. The aetiology of epilepsy was cerebrovascular (40.9%), trauma (9.8%), tumour (7.1%), dementia (6.5%), metabolic (1.8%), toxic or infectious (1.6% each) and was unknown in 30.7% of patients. Aetiologies like cerebrovascular disease or dementia increased (cerebrovascular 38.3-44.0% (ns), dementia 4.0-13.6%; x 2 = 13.7, p < 0.001) while others were less frequent (trauma 11.5-6.4% (ns), tumour 8.9-3.2%; x 2 = 4.4, p < 0.05) when patients aged between 65 and 74 years were compared to those aged between 75 and 84 years. Of all patients, 13.4% had previously been treated with two different AEDs and 0.4% had three previous antiepileptic treatments. Concomitant diseases (other than epilepsy) were noted in 82.7% of patients. Two-thirds had one or two concomitant diseases with hypertension (33%), diabetes (12.2%), coronary artery disease (7.5%) and depression (4.5%) being the Table 1 Characteristics of patients exposed to medication (safety population n = 491) and those with complete follow-up data (PP population n = 364). 
Results

Safety population
Per-protocol population
The per-protocol population (PP population, n = 364), consisted of 197 (54%) men and 167 women (46%) with a mean age of 72.1 years (SD 5.7, range 65-101, median 71) and a mean duration of epilepsy of 12.9 years (SD 16.5, range 0-75, median 5). Two hundred and sixty-six patients (73.1%) were between 65 and 74 years old, 89 (24.5%) were between 75 and 84 years old, and 9 (2.5%) were 85 years or older. Seizure classification consisted of 33.8% patients with simple and 42.9% with complex-partial seizures, 52.7% also had secondary generalized seizures and in 17.3% of the patients generalized tonic-clonic seizures occurred without preceding seizure type. Generalized tonic-clonic seizures without preceding seizure type were more frequent in younger (65-74 years) than in older (75-84 years) patients (19.5% vs.
10.1%; x 2 = 4.2, p < 0.05). In the PP population the aetiology of epilepsy was cerebrovascular (40.1%), trauma (12.1%), tumour (6.9%), dementia (5.2%), metabolic (1.6%), toxic (1.4%), infectious (1.9%) or unknown (30.8%). Like in the safety population, aetiologies like cerebrovascular disease (37.6% vs. 44.9%, ns) or dementia (3.4-11.2%, x 2 = 8.1, p < 0.01) increased with age while others were less frequent (trauma 13.9-7.9% (ns), tumour 9.0-1.1%, x 2 = 6.4, p < 0.05) when patients aged between 64 and 74 years were compared to those aged between 75 and 84 years. Most patients had only one previous AED treatment (86.2%). Two or more previous AED treatments were reported in 70 patients (13.8%) of the PP population. Given the inclusion criteria all patients were at least on one other AED when included into the study. The most frequent concomitant AEDs were valproic acid and carbamazepine (Table 2 ).
Levetiracetam dosage
The Levetiracetam dosage of the safety population is shown in Fig. 1 [ ( ) T D $ F I G ] Fig. 1 . Percentage of patients taking LEV as add-on treatment (mg per day) at study entry and 3, 6, and 12 months follow-up.
10.8% at 12 month follow-up (Fig. 1) . At the last follow-up visit, older (75-84 years) patients received lower LEV dosages than younger (65-74 years) patients (>1000 mg/day 37.0% vs. 65.5%, x 2 = 22.9, p < 0.001). Gender, duration of epilepsy or the number of previous AED treatments did not influence the LEV dose.
In the PP population the initial mean daily dosage of LEV was 797.4 (SD 318 mg, range 250-3000 mg, median 1000 mg) 54.9% receiving 1000 mg and 36.5% receiving 500 mg per day. A change of dose occurred most often at first follow-up (3 months, 49.2%, mean daily dose 1606 mg, SD 660.8 mg). At 6 and 12 months further changes were made in 22.3% and 15.7% of patients and mean daily dosage was 1 818.8 mg (SD 708.2 mg) and 2155.7 (SD 869.1 mg), respectively. In 40.1% the patient's dosage was increased; in 19.5% to 1 000 mg, in 9.6% to 1500 mg and in 3.8% to 2000 mg. Overall, median daily doses of the PP population were not different from the safety population, i.e. 1000 mg after the first visit, and 1500 mg, 2000 mg and 2000 mg at 3, 6 and 12 months follow-up. Dose increases were done more frequently in patients aged 65 to 74 years compared to patients aged between 75 and 84 years (25.8% vs. 35.3%, X 2 = 16.5, p < 0.001). In 50.8%, 46.2% and 83.5% of patients the LEV dosage remained unchanged at 3, 6 and 12 months follow-up.
Safety
Safety data analysis was based on the 491 patients of the safety population. Overall, LEV was well tolerated. At least one adverse event (AE) was experienced by 53 (10.8%) of the patients during the treatment period. Overall, 97 AEs were reported, of which 35 AEs in 19 patients (3.9% of the safety population) were classified as serious. Table 3 lists the reported adverse events. A total of 18 (3.7%) patients discontinued the trial because of intolerable side effects (irritability, dizziness, insomnia).
Most AEs were of mild or moderate intensity and known to occur with LEV treatment. 13 AEs regarding mood or affective symptoms (restlessness, irritability or aggression, depression) were present in 15 of 491 patients (3.1%) often in combination. Other common AEs were fatigue (1.2%) or gait instability (1%) or vertigo (1%). The AE outcome was classified as ''resolved'' in 77.3%, ''yet unresolved'' in 7.6%, and ''unknown'' or ''no information'' in 15.2%. In two patients irritability led to termination of the trial. There was no difference in the starting dosage of LEV between patients with and without AEs. Nine patients died during the course of the study. None of the deaths reported were related to the intake of Levetiracetam according to the assessments of the investigator and the sponsor. Eight patients had to be admitted to the hospital due to seizures (1.6%). In these, no case of status epilepticus was reported and the outcome was resolved in six and unknown in two. The majority of serious adverse events was classified as ''unlikely'' related to the study medication (Table 3) and consisted of medical events typically occurring in this age group. At 12 months follow-up the self assessment of tolerability was considered as ''very good'' by 70.1% of physicians and 62.9% of patients in the PP population (Fig. 2) .
Efficacy
Efficacy was analysed based on the PP population (n = 364), which excluded patients with missing study visits. In the 12 months prior to entry to the study the mean monthly seizure frequency was 7.0 (SD 8.7, range 1-85, median 4). Seizure frequency was higher in younger elderly patients (65-74 years) compared to older patients (75-84 years) (7.8 AE 9.7 vs. 5.1 AE 5.1, t = 2.5, p < 0.05). Seizure frequency was lower in patients with a duration of epilepsy of one year or less compared to those with 2-5 year duration of disease (5.8 AE 7.2 vs. 8.6 AE 8.6, t = 2.2, p < 0.05).
Mean total monthly seizure frequency was 1.7 (SD 2.9, range 0-29, median 1) at 3, 1.2 (SD 2.6, range 0-30, median 0) at 6, and 1.4 (SD 6.6, range 0-99, median 0) at 12 months, a reduction of 75.7%, 82.9% and 80.0% relative to baseline. Using analysis of variance with ''time'' as independent factor reduction of overall seizure frequency compared to baseline was significant (f(3) = 116.8, p < 0.0001) (Fig. 3) . Post hoc t-tests revealed that this was valid for all visits (3 month p < 0.0001, 6 month p < 0.0001, 12 months p < 0.0001). There was no difference in seizure freedom rates at 12 months between patients at 3000 mg/day and those on a daily dose of 2000 mg or less. A significant reduction of seizures was seen in all seizure types, in particular with secondary generalized tonic-clonic seizures at 12 months follow-up (reduction of 88.2%, p < 0.0001). Seizure frequency was slightly less reduced with simple partial seizures (73.9%, 78.3% and 69.6% at 3, 6, and 12 months).
Seizure freedom over the preceding period of observation (i.e. 3, 6, or 12 months) was reported by 42% of patients at 3 in 57.7% at 6, and 58% at 12 month follow-up visits. Overall, 28.6% of patients became seizure free in the first three months following introduction of Levetiracetam and had no further seizures over the 12 month study duration. Another 15.7% of patients reported seizure Table 3 Incidence of non-serious and serious adverse events in n = 491 patients receiving levetiracetam adjuctive therapy (safety-population).
Adverse event (in n = 34 patients) N % freedom from 3 and 13.5% from 6 months onwards till the end of the study.
At the 12 month follow-up visit, efficacy was rated as ''good'' or ''very good'' by 90.1% of physicians and 89.6% of patients (Fig. 2) .
Discussion
This study had an open label, uncontrolled, observational design and as such, conclusions of treatment effects of LEV in the elderly can only be tentative. A randomized, double-blind comparator controlled trial is ongoing to come to a more definite conclusion. 20 However, the data presented seems to justify such an effort as adding LEV to a current AED regiment in elderly patients with uncontrolled focal epilepsy was found to be associated with only a small number of adverse effects, significant reduction of seizure frequency and was judged positively by the great majority of patients and physicians. The main limitation of the study is the open-label, observational design. Potential problems arise from various biases, the quality of the data and the exploratory nature of the analysis. The lack of a comparative patient group as a control, the open design possibly causing treatment bias and the possible underreporting of adverse events only based on spontaneous reporting compared to controlled trials might be additional problems affecting the results. Another potential confounder of the present study was that efficacy analysis was based on the per protocol population, which might exclude patients with a negative initial treatment effect and bad tolerance. On the other hand, compared to controlled clinical trials, observational studies offer greater access to large, diverse populations giving a more naturalistic picture of everyday practice. Patient selection in observational studies is less influenced by the rigorous inclusion criteria of controlled trials and they may be important to detect adverse reactions that are uncommon. In addition, they may be valuable to obtain data upon general acceptance of a drug. In fact, because of co-morbidities and age-related issues patient recruitment in the elderly was a major problem in previous controlled trials. 21 Moreover, controlled trials particularly in the field of epilepsy often are too short to evaluate long-term treatment responses. 9 There are only four reports in small patient groups (n = 14-35) using LEV in elderly patients with epilepsy and in all of these trials LEV was used as first AED in monotherapy. [15] [16] [17] [18] In these open, observational or retrospective trials seizure freedom rates at 6-18 months follow-up ranged from 61 to 82% and discontinuation rates due to intolerability varied from 3 to 16%. [15] [16] [17] [18] In addition, the safety and efficacy data of the subsets of elderly (!65 years) patients receiving LEV as add-on therapy were reported from two open-label, 16-week, phase IV trials. 22, 23 The 50%, 75% responder rates and seizure freedom rates were 76.9, 56.9 and 40% in n = 78 22 and 65.2, 46.4 and 31.9% in n = 69 23 patients, respectively. In the present study, seizure freedom at 12 months could be achieved in 58% of patients and drop-out rate due to adverse effects was 3.7%. The relatively low seizure-freedom rate in our series is most likely due to the difference in patient population. We only included patients who failed at least one monotherapy. Therefore, our population most certainly was more difficult to treat given the sharply declining probability that subsequent drugs succeed after failure of monotherapy. 24 In other hand, a 3-month seizure freedom rate for all seizures of 75.7% in our trial was higher compared to previous add-on LEV trials, again reflecting differences in patient population. 22, 23 The higher drop-out rate in most previous monotherapy trials (i.e. 54% at 6 month in Brodie et al. 13 )
could be explained with differences in titration and by the fact that [ ( ) T D $ F I G ] newly diagnosed patients might be more sensitive towards side effects than patients that are already used to anticonvulsive therapy. In general, it should be noted that a large number of serious adverse events can be explained by medical conditions, complications of existing diseases, or death typically occurring in this age group. Only 11% of all patients were treated with the highest recommended daily dose of 3000 mg and two-thirds were managed with doses between 1000 and 2000 mg per day. This might reflect the good response to treatment of epilepsy occurring in the elderly. 2 Alternatively, old patients might require a lower LEV dose as compared to young patients because of reduced clearance. In support of the latter explanation, it has been shown that equivalent LEV serum levels can be achieved in older adults with a mean 40% lower dose than in young adults. 25 Taken together, the results of the present study seem to support the notion that a low dose of LEV might be sufficient in the elderly. In adults, a number of double-blind, placebo-controlled clinical trials have confirmed that LEV is effective and well-tolerated as add-on treatment in patients with focal epilepsy. 12, [26] [27] [28] However, the mean age of patients in these add-on trials was around 36 years making it difficult to judge upon the efficacy and tolerability of levetiracetam in the elderly. In addition, differences in study design and patient selection, with most patients having medically refractory long-standing epilepsy and multiple AEDs, greatly impede a comparison to the present study.
Comparison of individual observational studies is not viable because each study includes different patient populations, adopts different designs, and uses different analytical methods. With these limitations in mind, how does efficacy of add-on LEV compare to observational trials using other AEDs? In this study, complete seizure freedom was achieved in 58% and mean total monthly seizure frequency dropped by 80.0% at 12 months followup. Cho et al. 29 reported a mean reduction in mean seizure frequency of 47% using topiramate at 12 months in young adults with chronic epilepsy who failed 4.8 pervious AED treatments. In the elderly (n = 222), lamotrigine in monotherapy at a mean daily dose of 72 mg led to a mean reduction of 89% of seizure frequency over a period of one year with only 15 adverse events in nine patients. 30 There may be biases towards a more favourable outcome. For example, we do not know the reasons for drug failure of the first drug of those included. Some patients may have been ''pseudo-resistant'' to the first drug i.e. due to noncompliance, insufficient doses of the first drug due to side-effects, or wrong diagnosis with inappropriate treatment. 31 Information about other treatment changes, which may have occurred in parallel with the change of medication under investigation, was not collected during the trial and might have improved seizure control. Nevertheless, taken together the results of this study suggest that LEV add-on therapy is well tolerated and associated with a significant improvement of seizure control in elderly patients with partial epilepsies, which is in general agreement with previous long-term observational studies with this drug. 32 Monotherapy remains the treatment of choice for newly diagnosed epilepsy and polytherapy with more than one AED is considered after at least one failure of a monotherapy regimen only. This therapeutic strategy is driven by concerns of excessive drug load and increased toxicity what is of particularly relevance in elderly patients. Thus, combinations of AEDs should be carefully selected based not only on efficacy but also on a favourable pharmacokinetic profile and toxicity. From this perspective LEV seems a favourable drug given its pharmacological profile with rapid and complete oral absorption, linear pharmacokinetics and a low potential for clinically significant pharmacokinetic drug interactions. 33 The results of our study support efforts to challenge current treatment guidelines through randomized, controlled trials in the elderly comparing LEV with other established AEDs. Conflicts of interest KJW received consultation/advisory board/speaking honoraria from UCB, Pfizer, Eisai, Janssen-Cilag, GSK, and Desitin. UCB also sponsored research for which he served as primary investigator (IIT). SK received funding for trips from UCB to scientific meetings and received speaker honoraria from Pfizer and UCB. ET has acted as a paid consultant to Sanofi-Aventis, Pfizer, J&J, Eisai and UCB. He has received unrestricted research funding from GSK and UCB and speakers honoraria from Desitin, Pfizer, Novartis, GSK, Sanofi-Aventis, UCB, Eisai, Gerot, Cyberonics, and J&J. GK has received grants and research support from GSK and UCB and consultation/advisory board/speaking honoraria from Desitin, Eisai, GSK, JanssenCilag, J&J, Pfizer, and UCB in the last 3 years.
